guest ::
| Home > Publications database > Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. > print |
| Home > Publications database > Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. > print |
| 001 | 130861 | ||
| 005 | 20240228143502.0 | ||
| 024 | 7 | _ | |a 10.1038/srep25467 |2 doi |
| 024 | 7 | _ | |a pmid:27140836 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC4853774 |2 pmc |
| 037 | _ | _ | |a DKFZ-2017-05939 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 000 |
| 100 | 1 | _ | |a Werner, Simone |0 P:(DE-He78)6c57e61dc44a62313e7075a0cefbb086 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. |
| 260 | _ | _ | |a London |c 2016 |b Nature Publishing Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1522241470_30777 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Autoantibodies against tumor-associated antigens (TAAs) have been suggested as biomarkers for early detection of gastric cancer. However, studies that systematically assess the diagnostic performance of a large number of autoantibodies are rare. Here, we used bead-based multiplex serology to simultaneously measure autoantibody responses against 64 candidate TAAs in serum samples from 329 gastric cancer patients, 321 healthy controls and 124 participants with other diseases of the upper digestive tract. At 98% specificity, sensitivities for the 64 tested autoantibodies ranged from 0-12% in the training set and a combination of autoantibodies against five TAAs (MAGEA4 + CTAG1 + TP53 + ERBB2_C + SDCCAG8) was able to detect 32% of the gastric cancer patients at a specificity of 87% in the validation set. Sensitivities for early and late stage gastric cancers were similar, while chronic atrophic gastritis, a precursor lesion of gastric cancer, was not detectable. However, the 5-marker combination also detected 26% of the esophageal cancer patients. In conclusion, the tested autoantibodies and combinations alone did not reach sufficient sensitivity for gastric cancer screening. Nevertheless, some autoantibodies, such as anti-MAGEA4, anti-CTAG1 or anti-TP53 and their combinations could possibly contribute to the development of cancer early detection tests (not necessarily restricted to gastric cancer) when being combined with other markers. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Chen, Hongda |0 P:(DE-He78)03c284fb24dee4c82200ce43e1e0340f |b 1 |u dkfz |
| 700 | 1 | _ | |a Butt, Julia Anna |0 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |b 2 |u dkfz |
| 700 | 1 | _ | |a Michel, Angelika |0 P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7 |b 3 |u dkfz |
| 700 | 1 | _ | |a Knebel, Phillip |b 4 |
| 700 | 1 | _ | |a Holleczek, Bernd |b 5 |
| 700 | 1 | _ | |a Zörnig, Inka |0 P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3 |b 6 |u dkfz |
| 700 | 1 | _ | |a Eichmüller, Stefan |0 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |b 7 |u dkfz |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 8 |u dkfz |
| 700 | 1 | _ | |a Pawlita, Michael |0 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da |b 9 |u dkfz |
| 700 | 1 | _ | |a Waterboer, Tim |0 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |b 10 |u dkfz |
| 700 | 1 | _ | |a Brenner, Hermann |0 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |b 11 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/srep25467 |g Vol. 6, no. 1, p. 25467 |0 PERI:(DE-600)2615211-3 |n 1 |p 25467 |t Scientific reports |v 6 |y 2016 |x 2045-2322 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:130861 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)6c57e61dc44a62313e7075a0cefbb086 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)03c284fb24dee4c82200ce43e1e0340f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 2 |6 P:(DE-He78)31d7c3e829be03400641f80b821ef728 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)8c4d3a946a1fcde2ded7e17651fd0ed7 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)e00d6a13ce5ea2af7bde67bac1319dd3 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 7 |6 P:(DE-He78)23fb8cfffbf2aa8eee5d51af417ad944 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 8 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 9 |6 P:(DE-He78)d99bad949ba3ae93859eedae5ac266da |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)6b4ebb9791b983b5620c0caaf3468e30 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2016 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b SCI REP-UK : 2015 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1150 |2 StatID |b Current Contents - Physical, Chemical and Earth Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1040 |2 StatID |b Zoological Record |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b SCI REP-UK : 2015 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l Klinische Epidemiologie und Alternsforschung |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)G110-20160331 |k G110 |l Präventive Onkologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 2 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l Angewandte Tumor-Immunität |x 3 |
| 920 | 1 | _ | |0 I:(DE-He78)G010-20160331 |k G010 |l Geschäftsstelle |x 4 |
| 920 | 1 | _ | |0 I:(DE-He78)F020-20160331 |k F020 |l Molekulare Diagnostik Oncogener Infektionen |x 5 |
| 920 | 1 | _ | |0 I:(DE-He78)G182-20160331 |k G182 |l GMP Einheit Zelluläre Therapie |x 6 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G110-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G010-20160331 |
| 980 | _ | _ | |a I:(DE-He78)F020-20160331 |
| 980 | _ | _ | |a I:(DE-He78)G182-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|